이뮤셀코프(ICCC) 주가 전망 및 기업 분석 - PER·배당·실적·목표주가·RSI·MACD

ICCC

Immucell Corp

7월 27일 4:00 PM ET (한국 7/28 05:00)

$11.13

+0.10 ▲ +0.91%

🌙 7월 28일 8:12 AM ET (한국 7/28 21:12)

$10.91

-0.22 ▼ -1.98%

이뮤셀코프(ICCC) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시가총액

$101M

스몰캡

P/E

배당수익률

없음

52주 위치

87%

저점 +146% · 고점 -8%

애널리스트

B-

Fundamental health

vs. Biotechnology

수익성

Top 27%

성장

Top 39%

밸류에이션

Top 48%

재무 안정

Top 52%

💰 Is this stock pricier than usual right now?

Compared to this company's own recent 1년 (not other companies).

💎 Very cheap

Cheap

Typical

Pricey

Very pricey

Simply put — what you pay today to own $1 of this company's yearly earnings is 24원. Over the past 1년, it usually traded around 36원. One of the cheapest stretches of the past 1년.

Pricy doesn't mean bad — it means expectations are already baked in.· based on 1 profitable years

Index ⓘ	-	P/E ⓘ	-	EPS (ttm) ⓘ	-0.06	Insider Own ⓘ	37.77%	Shs Outstand ⓘ	9.1M	Perf Week ⓘ	-0.18%
Market Cap ⓘ	0.10B	Forward P/E ⓘ	-	EPS next Y ⓘ	-	Insider Trans ⓘ	0.23%	Shs Float ⓘ	5.6M	Perf Month ⓘ	12.54%
Enterprise Value ⓘ	0.11B	PEG ⓘ	-	EPS next Q ⓘ	-	Inst Own ⓘ	15.03%	Short Float ⓘ	0.25%	Perf Quarter ⓘ	33.21%
Income ⓘ	-0.00B	P/S ⓘ	3.36	EPS this Y ⓘ	-	Inst Trans ⓘ	0.94%	Short Ratio ⓘ	0.46	Perf Half Y ⓘ	77.8%
Sales ⓘ	0.03B	P/B ⓘ	3.46	EPS next 5Y ⓘ	-	ROA ⓘ	-1.22%	Short Interest ⓘ	0.01M	Perf YTD ⓘ	80.98%
Book/sh ⓘ	3.22	P/C ⓘ	14.79	EPS past 3/5Y ⓘ	29.01% 4.06%	ROE ⓘ	-1.88%	52W High ⓘ	-8.02% ($12.10)	Perf Year ⓘ	68.38%
Cash/sh ⓘ	0.75	P/FCF ⓘ	29.79	Sales past 3/5Y ⓘ	14.19% 12.5%	ROIC ⓘ	-1.36%	52W Low ⓘ	146.24% ($4.52)	Perf 3Y ⓘ	102%
Dividend Est. ⓘ	-	EV/EBITDA ⓘ	20.96	EPS Y/Y TTM ⓘ	4.9%	Gross Margin ⓘ	42.59%	Volatility(W/M) ⓘ	4.15% 5.55%	Perf 5Y ⓘ	13.51%
Dividend TTM ⓘ	-	EV/Sales ⓘ	3.56	Sales Y/Y TTM ⓘ	9.64%	Oper. Margin ⓘ	8.35%	ATR (14) ⓘ	0.52	Perf 10Y ⓘ	58.1%
Dividend Ex-Date ⓘ	-	Quick Ratio ⓘ	2.6	EPS Q/Q ⓘ	33.21%	Profit Margin ⓘ	-1.82%	RSI (14) ⓘ	57.22	Recom ⓘ	-
Dividend Gr. 3/5Y ⓘ	-	Current Ratio ⓘ	4.82	Sales Q/Q ⓘ	28.39%	SMA20 ⓘ	2.59% ($10.85)	Beta ⓘ	0.55	Target Price ⓘ	-
Payout ⓘ	-	Debt/Eq ⓘ	0.44	Earnings ⓘ	2026/8/13	SMA50 ⓘ	9.13% ($10.2)	Rel Volume ⓘ	0.5	Prev Close ⓘ	$11.03
Employees ⓘ	73	LT Debt/Eq ⓘ	0.38	EPS/Sales Surpr. ⓘ	-	SMA200 ⓘ	50.43% ($7.4)	Avg Volume(3M) ⓘ	0.03M	Price ⓘ	$11.13
IPO ⓘ	1987/5/5	Option/Short ⓘ	No/Yes			Trades ⓘ	435	Volume ⓘ	15,242	Change ⓘ	0.91%

Quarterly earnings trend SEC filings · USD

24.6

24.9

24.12*

25.3

25.6

25.9

25.12*

26.3

Revenue Net income 최근 분기: 매출 $10M (YoY +28%) · 순이익 $2M (YoY +34%)

* Q4 figures are derived from the annual filing (10-K) · loss-making quarters are underlined in red

📊 Immucell Corp (ICCC) Investment Analysis

What kind of company is Immucell Corp?

이뮤셀코프(ICCC) 방어주

Healthcare · Biotechnology

Small-Cap — Low Volume, High Volatility

🐄 Elanco (ticker: ELAN) is an animal healthcare company that improves the health and productivity of dairy and beef cattle. The company develops, manufactures, and sells oral immunity products to prevent diarrhea (scours) in newborn calves, as well as diagnostic and therapeutic products for dairy cow mastitis, primarily operating in the US market.

Learn more about Immucell Corp →

Market Cap

$0.1B

Approx. KRW 0.1 trillion

⚖️ 0% of Samsung Electronics

Market Cap Rank4530

Employees73people

IPO1987/05/05

Current Price$11.13 ≈ 15,248원

NASD · USA

Key Events

⏰ Upcoming events

🔔 Earnings release D-16

8월 13일 (목) · 장 마감 후

🎯 Ex-dividend date

No scheduled dividends

📜 Recent events

🔔 Earnings release 2026년 5월 14일 (목) · 장 마감 후

🔔 Earnings release 2026년 3월 4일 (수) · 장 마감 후

Is it profitable?

Financially sound but profitability is low

Losses or thin margins — early-stage growth or weakening competitiveness

Profitability — How efficiently it makes money

Operating Margin

Profit kept from selling products and services (higher is better)

8.3%

✓ 우수

My positionTop 5%

Low range Average High range

Biotechnology 초소형주 Median -778.0% · Top tier

💡 일반적으로 10% 이상이면 양호, 20% 이상이면 우수

Net Margin

Share of revenue left after taxes and interest are paid

-1.8%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

Gross Margin

Profit after subtracting raw-material costs only (signals product competitiveness)

42.6%

✓ 평균

My positionMid-range

Low range Average High range

Biotechnology 초소형주 Median 53.4% · Bottom 45%

💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)

ROE

Annual return earned on shareholders' equity (15%+ is strong)

-1.9%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

ROA

Annual earnings relative to total company assets

-1.2%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

ROIC

Return generated per dollar invested in the business

-1.4%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

Financial health — Debt & liquidity burden

Debt-to-Equity (D/E)

Debt relative to equity (lower is healthier)

0.44

✓ Healthy debt

My positionMid-range

Low range Average High range

Biotechnology Median 0.05

💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)

Current Ratio

Liquid assets available to cover liabilities due within a year

4.82

✓ 평균

My positionMid-range

Low range Average High range

Biotechnology Median 5.75

💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의

Quick Ratio

Liquid assets excluding inventory, available for immediate use

2.60

✓ 양호

My positionMid-range

Low range Average High range

Biotechnology Median 5.47

💡 1.0 이상이면 안전, 0.5 미만이면 주의

* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Outlook data is insufficient

Analyst estimates and price targets have not been collected.

Did earnings meet expectations?

Insufficient historical earnings data

No analyzable past earnings releases have been collected yet.

Is it growing?

Average Growth

Mid-range within the industry

Healthy, Balanced Growth EPS and revenue are both growing steadily — a sustainable growth profile

📊 How much has it grown? (actual results)

Past 3-Year EPS

Actual average annual EPS growth over the past 3 years

+29.0%

평균

My positionMid-range

Low range Average High range

방어주 초소형주 Median 30.0% · Bottom 49%

Past 5-Year EPS

Actual average annual EPS growth over the past 5 years

+4.1%

평균

My positionMid-range

Low range Average High range

방어주 초소형주 Median 16.4% · Bottom 38%

Past 5-Year Revenue

How much revenue grew over the past 5 years

+12.5%

우수

My positionTop 25%

Low range Average High range

방어주 초소형주 Median 2.1% · Top 19%

⚡ Short-term momentum

QoQ Revenue

Revenue change from the previous quarter (short-term momentum)

+28.4%

우수

My positionTop 25%

Low range Average High range

방어주 초소형주 Median -4.5% · Top 24%

* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

New to investing terms? Look it up in the financial dictionary →

Has the stock risen over the long term?

Long-term weakness — -55%p below the market

ICCC +13.5% · S&P 500 +68.3%

Excess return vs. market (price-based, ex-dividends)

5-year basis

vs S&P 500

-54.8%p

Significantly behind the market

vs Health Care (XLV)

-11.0%p

behind the sector average

1-year basis

vs S&P 500

+52.4%p

well ahead of the market

vs Health Care (XLV)

+48.7%p

well ahead of the sector average

Rank among peers

5-year return Top among peers Based on 245 peers

1-year return Top 10% Based on 315 peers

Current position within 52-week range

Low (-146.2%p) High (-8.0%p)

Current price is 146.2% above the 52-week low and 8.0% below the 52-week high

Recent risk (last 120 trading days)

Max drawdown

-11.8%

Annualized volatility

52.8%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

close
BB Upper
BB Mid
BB Lower
Tenkan
Kijun
Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🟢

Current diagnosis · 2026-07-27

Uptrend zone

Current price $11.13 above the midline ($10.85). Normal upward flow. Above the Ichimoku cloud (bullish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🟡

Current diagnosis · 2026-07-27

Neutral zone — weak trend

MACD 0.328 · Signal 0.366 · Hist -0.038. Weak directional bias.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🟢

Current diagnosis · 2026-07-27

Bullish zone

RSI 57.2 (above the neutral level of 50). Buying pressure leads, supporting a steady rise. Stoch %K is also 42.9.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

In line with the industry average

Cheap on Vs. Sales·Vs. Cash Flow, Pricey on Vs. Assets

💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.

🏢 Vs. Assets Pricey

🧾 Vs. Sales Cheap

💧 Vs. Cash Flow Cheap

🏢 Vs. Assets

PBR Price-to-Book Ratio

Price vs. the company's asset value — below 1 trades cheaper than assets

3.46x

✓ Pricey

My positionBottom 25%

Low range Average High range

Biotechnology 초소형주 median 1.35x · Bottom 24% — expensive within the industry

💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)

🧾 Vs. Sales

PSR Price-to-Sales Ratio

Market cap vs. revenue — lower is cheaper relative to sales

3.36x

✓ Cheap

My positionMid-range

Low range Average High range

Biotechnology 초소형주 median 11.24x · Around the industry average

💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)

💧 Vs. Cash Flow

EV/EBITDA Enterprise Value Multiple

Total enterprise value ÷ operating cash earnings — a benchmark for M&A

20.96x

✓ Cheap

My positionMid-range

Low range Average High range

Biotechnology median 22.58x · Around the industry average

💡 EV/EBITDA 10 이하 저평가, 20 이상이면 고평가 (M&A 밸류 기준)

💧 Vs. Cash Flow

P/FCF Price-to-Free-Cash-Flow Ratio

Price vs. actual cash generation — lower means more efficient

29.79x

✓ Fair

My positionMid-range

Low range Average High range

Biotechnology median 18.43x · Around the industry average

💡 P/FCF 20 이하면 현금창출 대비 저평가 (실질 수익성 기준)

* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.

As of: Recent snapshot · Peer group: Biotechnology 초소형주

Who owns it?

Ownership flow is positive

Insider modest net buying +0.2% · Institutional modest net buying +0.9% · Short interest light 0.3%

📈 Recent trading flow (6 months)

🧑‍💼 Insiders (executives & directors)

+0.2%

Insiders net buying

🏦 Institutions (funds & investors)

+0.9%

Institutions net buying

💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.

👥 Holdings composition

🏦 Institutions 15.0%

Retail-led

Healthcare 초소형주 Median 14.2%

🧑‍💼 Insiders 37.8%

Founder/management large holders (strong skin-in-the-game)

Healthcare 초소형주 Median 16.1%

👤 Retail investors (estimated) 47.2%

Everyone excluding institutions and insiders

Institutions Insiders Retail (est.)

📉 Short-selling metrics

Short ratio

0.3%

Low — limited short-side pressure

Healthcare 초소형주 Median 3.9%

Past 90 days Little change

Short interest days to cover

0.5 days

Days needed to close short positions using average trading volume

🧮 Share count

Total shares outstanding 9.1M주

Float (tradable shares) 5.6M주

* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding ICCC

ETFs with the highest weightings · 8 total shown

IWC

iShares Micro-Cap ETF

0.01%

$1.4B

DFAC

Dimensional U.S. Core Equity 2 ETF

0.00%

$47.5B

DFAT

Dimensional U.S. Targeted Value ETF

0.00%

$14.5B

DFSU

Dimensional US Sustainability Core 1 ETF

0.00%

$2.2B

DXUV

Dimensional US Vector Equity ETF

0.00%

$529M

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)

Sorted by market cap, largest first

Stock	Market Cap	PER	PBR	ROE	Dividend Yield	Change
ICCC This Stock	$100.7M	-	3.5 ▼	-1.88% ▲	-	+0.9%
LLY	$1.13T	43.1 ▼	36.2 ▼	107.64% ▲	0.58% ▼	+0.1%
JNJ	$640.9B	30.8 ▼	7.5 ▼	25.74% ▲	2.02% ▲	+1.0%
ABBV	$453.9B	126.7 ▼	-	15221.82% ▲	2.67% ▲	-0.9%
UNH	$379.3B	26.9 ▼	3.9 ▼	12.49% ▲	2.16% ▲	-0.7%
MRK	$323.0B	36.8 ▼	7.0 ▼	18.97% ▲	2.5% ▲	-0.2%
Sector Avg	-	26.1	2.7	-48.83%	1.23%	-

FAQ

What kind of company is 이뮤셀코프(ICCC)?

이뮤셀코프(ICCC) belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of ICCC?

The market cap of ICCC is approximately $101M, ranking 4,530 within its sector.

What is the 52-week high and low for ICCC?

ICCC has recorded a 52-week high of $12.10 and a low of $4.52.

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.